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Abstract: Activation of the renin-angiotensin system plays a major role in cardiovascular 
morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the 
  subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects 
of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along 
the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, 
to patients with heart failure. This article reviews the implications of these trials for the optimal 
management of cardiovascular risk.
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Introduction
Cardiovascular diseases remain highly prevalent in western industrialized countries and 
are estimated to cause more than 4.3 million cardiovascular deaths per year in Europe.1 
While lifestyle intervention is essential for risk reduction, pharmacological intervention 
is further necessary to improve individual cardiovascular risk factors, such as lipid 
status, diabetes, and hypertension. Among the commonly used antihypertensives 
(diuretics, β-blockers, calcium channel blockers, or angiotensin-converting enzyme 
inhibitors), in recent years the angiotensin II receptor blockers (ARBs) have been 
the focus of a number of large clinical outcome trials in patients at various stages 
of the cardiovascular continuum. This article reviews the implications of these trial 
results for the optimal management of cardiovascular risk.
Continuum of cardiovascular disease progression
The concept of a cardiovascular disease continuum was first described in the early 1990s, 
and has since become established as a convenient tool to understand the progressive 
nature of cardiovascular pathophysiology.2–5 Under this paradigm,   cardiovascular 
events are the late complications in a sequence of steps of a progressive pathogenic 
process, beginning with endothelial dysfunction and manifest atherosclerotic lesions, 
which progress to target organ damage and end-organ failure.
The concept of the cardiovascular disease continuum has implications for assessing 
the clinical significance of trial results, because the patients recruited will typically be 
placed at a specific stage on the continuum, ie, those with cardiovascular risk factors, 
those with or without manifest end-organ damage, or those already having a history 
of cardiovascular events. Furthermore, the sizes of the populations with   particular 
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continuum (Figure 1). Pathophysiological mechanisms 
alter along the cardiovascular continuum, but activation of 
the renin-angiotensin system with increased angiotensin II 
concentrations has been implicated at every stage and is 
therefore a prime candidate for intervention.
Angiotensin II contributes to many of the pathogenic 
processes that initiate and perpetuate cardiovascular disease. 
Key effects are the synthesis of reactive oxygen species and 
increased oxidative stress leading to endothelial dysfunction 
as the initial step in atherosclerosis.6 Additional pathogenic 
actions of angiotensin II include: vascular cell proliferation 
and migration of smooth muscle cells; expression of adhe-
sion molecules and chemokines that mediate adhesion and 
migration of the monocytes in the vascular wall; decrease in 
fibrinolysis; increase in platelet aggregation; and increase in 
procoagulative state through activation of plasminogen acti-
vator inhibitor 1 expression.6,7 Given the pivotal role played 
by the renin-angiotensin system in cardiovascular disease, 
treatment with angiotensin-converting enzyme inhibitors 
or ARBs provides protection throughout the cardiovascular 
continuum.
Outcome studies with ARBs
Clinical trials have evaluated the effects of ARBs in primary 
and secondary prevention. Although clinical trials have been 
conducted in patients with myocardial infarction, the study 
population could be further divided into patients at the early 
stages of the cardiovascular continuum, patients at high risk 
of cardiovascular disease, and patients with left ventricular 
dysfunction or even chronic heart failure.
early stages of the cardiovascular 
continuum
Three ARB outcome studies recruited patients at a relatively 
early stage of the cardiovascular continuum with hyperten-
sion and additional risk factors. In the Losartan Intervention 
For Endpoint (LIFE) reduction in hypertension study, over 
9000 patients with moderate to severe hypertension (baseline 
blood pressure 174/98 mmHg) and left ventricular hypertro-
phy were included.8 Compared with treatment using atenolol, 
the ARB losartan improved the primary composite endpoint 
(cardiovascular mortality, stroke, and myocardial infarc-
tion) significantly (relative risk [RR]: 0.87, 95% confidence 
interval [CI]: 0.77–0.98, P = 0.021) with similar reductions 
in blood pressure. However, due to side effects, β-blockers 
have recently been debated as a first-line treatment in patients 
with hypertension and are no longer recommended in some 
countries.9 Thus, the results of the LIFE trial may be some-
what limited for clinical practice regarding atenolol as the 
comparator substance.
The Valsartan Antihypertensive Long-term Use 
Evaluation (VALUE) trial randomized 15,313 patients with 
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Figure 1 Angiotensin receptor blocker clinical trials along the cardiovascular continuum.
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hypertension and additional risk factors (45.8% coronary 
heart disease, 31.7% diabetes, 33.0% high cholesterol) to 
either valsartan or amlodipine. Although the two regimens 
were similar on the primary composite outcome, there was 
a difference in favor of amlodipine in the early stages of 
the trial that may be explained by a more pronounced blood 
pressure reduction after 1 month and 1 year (P , 0.001, 
Figure 2).10 Amlodipine was superior to valsartan on the 
incidence of myocardial infarction, which may also have been 
a blood pressure-related effect. However, valsartan reduced 
the new onset of diabetes significantly (13.1% vs 16.4%, 
hazard ratio [HR]: 0.77, 95% CI: 0.69–0.86, P , 0.0001), 
which is in line with the results of the LIFE trial.
Similar to VALUE, the Kyoto Heart Study included 
patients (n = 3031) with hypertension and additional risk 
  factors.11 The trial was placebo-controlled, with valsartan used 
as an add-on treatment. Although baseline blood pressure was 
similar (157/88 mmHg), in-trial blood pressure reductions 
were somewhat greater than those seen in the VALUE trial 
(-24/-12 mmHg), but without any difference between the 
treatment groups. Moreover, concomitant antihypertensive 
treatment was comparable in both treatment arms; thus results 
might be interpreted as blood pressure-independent effects 
of the ARB. Add-on treatment with valsartan significantly 
reduced the primary composite endpoint (HR: 0.55, 95% CI: 
0.42–0.72, P = 0.00001) as well as rate of stroke (HR: 0.55, 
95% CI: 0.3–0.9, P = 0.01488), and again new onset of diabe-
tes (HR: 0.67, 95% CI: 0.5–0.9, P = 0.02817). However, the 
results are limited by the open-label design, particularly given 
that the superior efficacy regarding the primary composite 
endpoint was strongly driven by the relatively soft endpoints 
of angina and transient ischemic attack.
High cardiovascular risk
A very substantial population is those patients who have 
controlled blood pressure, but remain at high cardiovascular 
risk due to the presence of atherosclerotic lesions or even 
patients with a prior cardiovascular event but without heart 
failure. Moreover, approximately 50% of patients with type 2 
diabetes have microvascular or macrovascular complications, 
placing them in the high-risk category for a future cardio-
vascular event.12
Two ARB trials have recruited patients from this stage 
of the cardiovascular continuum. The Ongoing Telmisartan 
Alone and in Combination with Ramipril Global Endpoint 
Trial (ONTARGET) program recruited 25,620 patients 
with coronary, peripheral, or cerebrovascular disease, or 
diabetes with end-organ damage to receive treatment with 
telmisartan, ramipril, or the combination.13 It was thus 
notable for being the first major trial to compare an ARB with 
another blocker of the renin-angiotensin system (ramipril), 
which might be suggested as a gold standard for secondary 
prevention in patients with high cardiovascular risk in view 
of the Heart Outcomes Prevention Evaluation (HOPE) trial.14 
In ONTARGET, telmisartan and ramipril were similarly 
effective on the primary composite endpoint of cardiovascular 
death, myocardial infarction, stroke, or hospitalization for 
heart failure (1423 of 8542 patients [16.7%] vs 1412 of 8576 
patients [16.5%], RR: 1.01, 95% CI 0.94–1.09; Figure 3), as 
well as for the individual component of cardiovascular death 
(7.0% vs 7.0%, RR: 1.00, 95% CI 0.89–1.12), and other 
outcomes of non-cardiovascular death (4.6% vs 4.8%, RR: 
0.96, 95% CI 0.83–1.10) and death from any cause (11.6% 
vs 11.8%, RR: 0.98, 95% CI 0.90–1.07). The combination 
was no more effective and was associated with significantly 
increased side effects.
The Telmisartan Randomized Assessment Study in 
ACE-I Intolerant Subjects with Cardiovascular Disease 
(TRANSCEND) trial had a design similar to that of 
ONTARGET, but included angiotensin-converting enzyme 
inhibitor-intolerant patients, who are considered likely 
to represent 15%–20% of the general population. Thus, 
patients in TRANSCEND received add-on treatment with 
telmisartan compared with placebo. There was a trend to 
superiority on the primary composite endpoint (465 of 
2954 patients [15.7%] vs 504 of 2972 patients [17.0%], 
HR: 0.91, 95% CI: 0.80–1.05), with the individual compo-
nent of cardiovascular death being similar (7.7% vs 7.5%, 
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Figure 2 Differences (∆) in SBP between treatment groups in the VALUe trial 
during consecutive time periods in the study, with odds ratios for primary endpoint 
cardiac morbidity and mortality.
Abbreviations: SBP, systolic blood pressure; VALUe, Valsartan Antihypertensive 
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HR: 1.03, 95% CI: 0.85–1.24, P = 0.778). The secondary 
endpoint (that matches the   primary endpoint in HOPE and 
did not include hospitalization for heart failure) reached 
statistical significance (13.0% vs 14.8%, HR: 0.87, 95% 
CI: 0.76–1.00, P = 0.048). Total mortality was similar in the 
telmisartan and placebo groups (12.3% vs 11.7%, HR: 1.05, 
95% CI: 0.91–1.22, P = 0.491).15 As in ONTARGET, con-
comitant medical treatment was excellent in TRANSCEND, 
with around 55% of patients receiving statins and 58% being 
treated with a β-blocker, respectively. Compared with the 
HOPE trial, background medical treatment improved mark-
edly in ONTARGET as well as in TRANSCEND, although 
the time difference was only 8 years (Table 1).16
The ONTARGET and TRANSCEND study populations 
differed from those in the LIFE, VALUE, and Kyoto Heart 
trials because they had well controlled baseline blood pressure 
and higher prevalence of cardiovascular disease (Table 2). 
This is reflected in the blood pressure reductions from baseline 
during the trial, which were relatively small in ONTARGET, 
at around -7/-5 mmHg, compared with reductions of around 
-15/-9 mmHg in VALUE, -24/-12 mmHg in Kyoto Heart, 
and -30/-17 mmHg in LIFE.
The Randomized Olmesartan and Diabetes Microal-
buminuria Prevention (ROADMAP) trial was a recent 
placebo-controlled study in patients without hypertension 
but with diabetes and additional risk factors, thus placing 
Primary composite outcome
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Figure 3 Relative risk of the primary outcome and of the main secondary outcome in the ONTARGeT trial. The dotted line indicates the noninferiority margin. 
Note: The P value indicates noninferiority of telmisartan compared with ramipril.
Abbreviations: CI, confidence interval; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial.
Table 1 Baseline medication usage (% of patients) in the HOPe,14 
ONTARGeT,15 and TRANSCeND® trials16
HOPE ONTARGET TRANSCEND
Recruitment completed 1995 2003 2004
ACe inhibitors 11.6 57.5 58.1
β-blockers 39.5 56.9 57.6
Diuretics 15.1 27.9 32.6
Oral anticoagulants 3.8 7.6 7.2
Statins 28.9 60.7 54.4
Abbreviations:  ACe,  angiotensin-converting  enzyme;  HOPe,  Heart  Outcomes 
Prevention evaluation; ONTARGeT, Ongoing Telmisartan Alone and in Combination 
with  Ramipril  Global  endpoint  Trial;  TRANSCeND,  Telmisartan  Randomized 
Assessment Study in ACe-i intolerant Subjects with Cardiovascular Disease.
them at increased cardiovascular risk.17 The primary endpoint 
was the time to first onset of microalbuminuria, which after 
adjusting for blood pressure differences was nonsignificant. 
The secondary endpoint was a composite of cardiovascular 
complications or death from cardiovascular causes, and there 
was no difference between olmesartan and placebo (which 
was reached by 96 of 2232 patients [4.3%] in the olmesartan 
group and by 94 of 2215 patients [4.2%] in the placebo group; 
HR: 1.00, 95% CI: 0.75–1.33, P = 0.99). However, deaths 
from cardiovascular causes were significantly higher with 
olmesartan (n = 15, 0.7%) than with placebo (n = 3, 0.1%; 
HR: 4.94, 95% CI: 1.43–17.06, P = 0.01), although deaths 
from any cause were not significantly different (26 [1.2%] 
patients vs 15 [1.7%] patients, HR: 1.70, 95% CI: 0.90–3.22, 
P = 0.10). A similar excess cardiovascular mortality with 
olmesartan was seen in Olmesartan Reducing Incidence 
of End Stage Renal Disease in Diabetic Nephropathy Trial 
(ORIENT).18 The cause of this excess mortality is unknown, 
but these results suggest that olmesartan should be used with 
caution in patients at high cardiovascular risk.
Heart failure or left ventricular systolic 
dysfunction
Compared with those at an early stage of the cardiovascular 
continuum, patients with heart failure tend to be older, and 
often have several comorbidities.19 Two trials have compared 
ARBs with captopril in patients with heart failure or left 
ventricular dysfunction after a recent myocardial infarction 
(#10 days). The Valsartan in Acute Myocardial Infarction 
Trial (VALIANT) compared valsartan, captopril, and the 
combination in nearly 15,000 patients, with an average 
follow-up of 2 years.20 The Optimal Therapy in Myocardial 
Infarction with the Angiotensin II Antagonist Losartan 
(OPTIMAAL) trial compared a relatively low dose of losar-
tan (50 mg once daily) with captopril 50 mg three times daily 
in 5477 patients and had a mean follow-up of 2.7 years.21 
Whereas VALIANT demonstrated clear equivalence on the 
primary endpoint (all-cause mortality) between valsartan Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and captopril, there was a trend for superiority of captopril 
over losartan in OPTIMAAL (HR: 1.13, 95% CI: 0.99–1.28, 
P = 0.07). Different results for losartan and valsartan might 
be explained by a lower cardiovascular risk of patients in 
OPTIMAAL than that of those enrolled in VALIANT. 
Furthermore, differences in dosing and titration regimens 
may have influenced the results, because blood pressure 
reductions in OPTIMAAL were lower than with valsartan 
in VALIANT.
The Evaluation of Losartan in the Elderly II (ELITE II) 
trial compared losartan 50 mg once daily with captopril 
50 mg three times daily in patients with chronic heart 
failure, and found both substances to be similarly effec-
tive in preventing all-cause mortality; however, there 
was a tolerability advantage to losartan.22 More recently, 
the Heart Failure Endpoint Evaluation of AII-Antagonist 
Losartan (HEAAL) study, which examined the effects of 
high-dose vs low-dose losartan on clinical outcomes in 
patients with heart failure, found that losartan 150 mg/day 
was more effective than 50 mg/day in reducing death or 
admission for heart failure (HR: 0.9, 95% CI: 0.83–0.99, 
P = 0.027),23 which suggests that losartan was underdosed 
in ELITE II. The beneficial effects of high-dose losartan 
were limited by a significantly increased number of side 
effects (renal impairment, hyperkalemia, hypotension), 
although discontinuation of study drug was similar for both 
treatment regimens.
In the Candesartan in Heart Failure: Assessment of 
Reduction in Mortality and Morbidity (CHARM) study, 
candesartan 32 mg/day reduced both cardiovascular deaths 
and hospital admissions compared with standard treatment 
(Figure 4). However, ARBs have not been found to benefit 
patients with heart failure with preserved ejection fraction 
in the CHARM-Preserved stratum, which is in line with 
the results of the Irbesartan in Heart Failure with Preserved 
Systolic Function (I-PRESERVE) trial.24,25
In patients with heart failure on hemodialysis, telmisartan 
80 mg/day reduced all-cause mortality (HR: 0.51, 95% 
CI: 0.32–0.82, P , 0.01) compared with best usual care, 
as well as hospital admissions for chronic heart failure and 
cardiovascular deaths.26
Safety of ARBs
A meta-analysis of five ARB trials involving 61,590 patients 
with new cancer data available found ARBs to be associated 
with a modestly increased risk of new-onset cancer (7.2% vs 
6.0%, RR: 1.08, 95% CI: 1.01–1.15, P = 0.016).27 However, 
this meta-analysis was criticized on methodological grounds, 
particularly given that it did not include some important 
trials.28 More recently, the most comprehensive assessment 
of ARBs and cancer to date has analyzed a total of 15 tri-
als involving 138,769 patients.29 ARBs as a class were not 
associated with increased risk of cancer compared with 
comparators (odds ratio [OR]: 1.00, 95% CI: 0.95–1.04), 
and there was also no increase in cancer risk with ARBs in 
combination with angiotensin-converting enzyme inhibitors. 
No individual ARB was associated with an increased risk of 
cancer. On the basis of existing clinical trials, there does not 
seem to be any reason to suspect ARBs of increasing the risk 
of cancer. By contrast, the cardiovascular disease benefits of 
these agents are well established.
Table 2 Baseline characteristics of ARB trials in patients at the early-to-mid stages of the CV continuum
Hypertension (%) Baseline SBP/DBP (mmHg) CAD (%) LVH (%) Stroke/TIA (%) PAD (%)
LiFe 100 174/98 16 100 8 6
VALUe 100 155/87 46 6 20 14
Kyoto Heart 100 157/88 23 8 4 N/A
ONTARGeT 69 142/82 74 13 20 14
TRANSCeND 76 141/82 74 13 22 11
Abbreviations: CAD, coronary artery disease; DBP, diastolic blood pressure; LVH, left ventricular hypertrophy; NA, data not available; PAD, peripheral arterial disease; 
SBP, systolic blood pressure; TiA, transient ischemic attack; LiFe, Losartan intervention For endpoint; VALUe, Valsartan Antihypertensive Long-term Use evaluation; 
ONTARGeT, Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial; TRANSCeND, Telmisartan Randomized Assessment Study in ACe-i 
intolerant Subjects with Cardiovascular Disease.
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Figure 4 Hazard ratio (candesartan vs control) of the all-cause mortality and CV 
death or hospital admission for chronic HF in CHARM-Overall, -Preserved, -Added 
and -Alternative.
Notes: P values for heterogeneity: *P = 0.37; †P = 0.33.
Abbreviations: CV, cardiovascular; HF, heart failure; CHARM, Candesartan in 
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Combination of ARBs and 
angiotensin-converting enzyme 
inhibitors
ONTARGET demonstrated no benefit from adding ARBs and 
angiotensin-converting enzyme inhibitors in patients at high 
cardiovascular risk without heart failure. For patients with 
chronic heart failure, results of the clinical trials diverge.
In the Valsartan Heart Failure Trial (Val-HeFT), addi-
tional treatment with valsartan 160 mg/day in patients with 
chronic heart failure, who were mostly (93%) being treated 
with an angiotensin-converting enzyme inhibitor, reduced 
hospital admission but did not reduce mortality.30 Similarly, 
VALIANT found no benefit on mortality, and an increase in 
adverse events from combination treatment with valsartan 
and captopril in post-myocardial infarction patients.20
The CHARM-Added stratum of the CHARM trials 
found a significant benefit of adding candesartan to ongo-
ing angiotensin-converting enzyme inhibitor therapy on the 
composite of cardiovascular death or hospital admission 
for chronic heart failure.31 This is suggestive of a difference 
between candesartan and valsartan due to dosing. Whereas 
CHARM-Added used the same target dose of candesartan 
in the monotherapy and combination arms, the combination 
arm in VALIANT received half the valsartan dose that the 
monotherapy arm received. However, patients in Val-HeFT 
received the higher valsartan dose of 160 mg without an 
effect on mortality.
Clinical implications
There is strong evidence suggesting a reduction of car-
diovascular risk when adding an ARB to evidence-based 
concomitant drug therapy. Candesartan and valsartan, and in 
part losartan at higher doses, have shown efficacy in patients 
with heart failure, while telmisartan has been shown to be 
effective in a broad range of patients at high cardiovascular 
risk due to existing atherosclerotic disease or diabetes with 
end-organ damage.
For patients in whom raised blood pressure represents a 
major contributory factor to their cardiovascular risk, such 
as those recruited into the LIFE and VALUE trials, the 
evidence for specific benefit with ARBs is less clear, due 
to the comparator substance in LIFE and more pronounced 
blood pressure reduction by amlodipine in the VALUE 
trial. Nevertheless, in these trials, ARBs were well or even 
better tolerated and significantly reduced the frequency of 
new-onset diabetes.
One clinical question remains: Should a specific ARB 
be selected, or can a class effect be assumed in patients 
at high risk of cardiovascular disease? Interpretation and 
extrapolation from ARB outcome trials remains difficult, 
because different populations with different background 
therapies were enrolled in those trials. Although differences 
in the outcomes of the various trials might hint towards 
possible intrinsic differences in efficacy, this remains 
speculative given that there are no head-to-head trials com-
paring different ARBs in cardiovascular risk patients.
Given the evidence of potentially important pharma-
cological differences, a precautionary approach should be 
adopted, with an ARB selected according to evidence from 
clinical trials, which directly inform their respective indica-
tions for clinical use, unless compelling reasons exist for 
selection of another drug.
Conclusion
Over the past decade, the 12 ARB outcome trials reviewed 
here have provided 384,000 years of patient data. These 
major cardiovascular outcomes studies offer unequivocal 
evidence that ARBs reduce cardiovascular risk. What 
remains uncertain is the extent to which reduction in risk 
differs or exceeds that available with other antihypertensive 
classes, due to pleiotropic effects of ARBs, and the degree 
to which the known pharmacological differences justify 
intraclass preferences.
ARBs have therefore justified their central role along 
with angiotensin-converting enzyme inhibitors in the 
management of cardiovascular risk, by demonstrating their 
efficacy along the cardiovascular continuum, from patients 
with risk factors, through those at high cardiovascular risk, 
to patients with heart failure. A number of factors should be 
considered in the selection of an antihypertensive agent to 
reduce cardiovascular events: antihypertensive efficacy, of 
course, but also factors such as cardiovascular prevention 
beyond lowering of blood pressure alone, tolerability, and 
the potential for combination therapy.
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